IDA Foundation and Macro-Eyes today announced a partnership to increase supply chain efficiency using data insights generated by STRIATA: Macro-Eyes software for precision matching supply to demand. The global health sector has been impacted heavily by the COVID-19 pandemic, and getting the most essential medicines and health supplies to low- and middle-income countries (LMICs) has become even more challenging. Globally, lead times have increased significantly since the onset of the pandemic.
This month, our QA Director Michiel de Goeje retired after 34 years of service at IDA Foundation. Bart van Osch, IDA’s new QA Director, has been working alongside Michiel for the past year, to ensure a thorough handover of responsibilities.
According to WHO, despite significant advances in driving down child mortality rates in recent decades, almost 5.2 million children under five still die every year from preventable and treatable diseases, most of whom are in low- and middle-income countries (LMICs). Leading causes are (pre-term) birth complications as well as preventable and/or treatable health issues such as malaria and measles.
The World Health Organization published the latest edition of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children last week, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.
A deteriorating humanitarian situation in Afghanistan means that an estimated 18 million people are currently in need of aid. Working closely with our customers, this week IDA will be shipping another 1000 IEHK (kits) from our warehouse in Tilburg, and over 1500 IEHK from our kitting facility in Dubai have already arrived. Aside from emergency kits, IDA also shipped 120 Pediatric Severe Acute Malnutrition (PED-SAM) kits, containing essential oral- and injectable- medication to treat young children who are suffering from medical complications caused by severe acute malnutrition. The warehouse teams are working 24/7 to make sure these essential supplies are reach Afghanistan - and those in need- as soon as possible.
IDA Foundation has partnered with Ferring Pharmaceuticals, who have developed heat-stable carbetocin (HSC), a product that can reduce the risk of PPH. HSC is more resistant against higher temperatures and increased humidity compared to oxytocin, making it very suitable for use in low- and middle-income countries. HSC is now being used in clinical practice for the first time in healthcare settings in India - with more LMICs following soon.
Last week, IDA Foundation supplied 228 pallets of kits to Afghanistan for WHO. The kits, which contain medical supplies and essential medicines, were loaded on two charter flights from our warehouse in Dubai. The WHO is working closely together with the Ministry of Public Health to distribute these supplies to health care facilities across the country.
At IDA Foundation we are committed to supporting health organisations in LMICs with the roll-out of vaccination programmes. We have already received our first orders, and we hope to supply vaccination-related products to many more customers. To facilitate and support those customers, we have created an overview of all the products needed for vaccination. By grouping these different items in one factsheet we hope to ease the ordering process.
In many low- and middle-income countries (LMICs), women often lack access to the right nutrients during pregnancy. Proper nutrition during pregnancy is essential for a healthy mother and for a healthy start of life for every newborn child. In line with Sustainable Development Goal (SDG) 3, IDA Foundation aims to support both maternal- and child-health, by supplying a broad range of products related to family planning, healthy pregnancies and safe births.
India is slowly recovering from a severe and devastating second COVID-19 wave, during which India reported 414.188 daily new cases at its highest peak on 7 May (WHO, 2021). Cities such as Mumbai in the state of Maharashtra have been hit especially hard by this wave.
IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of Ethambutol 100mg dispersible tablets for the treatment of drug-sensitive forms of tuberculosis.
One year into the global COVID-19 pandemic, much of the global focus is currently going to vaccination rollouts, but treatment options are still limited. However, dexamethasone, an essential medicine which has been around for decades (listed by WHO since 1977) – is one of the few approved treatments for severe and critically ill COVID-19 patients.
New partnership broadens access to oncology treatments across Latin America, Asia, Africa and the Western Pacific
Since the early start of the pandemic we have been supplying PPE and other urgent supplies to countries worldwide, and we have seen the effects of the unforeseen costs that come with it. Budgets need to be reassessed and customers must find a balance between products required and increased transport costs.
IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of ANTI-TUBERCULOSIS MEDICINES AND RELATED PRODUCTS for the treatment of DRUG-RESISTANT FORMS of tuberculosis to eligible manufacturers.
In this pandemic, QA remains vital as always, as we found ways to ensure continued supply of essential (PPE) products. As ADB's Jesper Pedersen commented: “The best practice for supply chain responsiveness and resiliency is to perform key aspects of quality assurance upfront to ensure parties involved in the manufacture of goods adhere to the applicable national or international standards of the items being produced. Quality control is then handled upon physical inspection of the goods to ensure the delivered items meet the agreed standards. This is exactly what we have seen so far in our relationship with IDA – the right goods, delivered at the right time, and to the agreed standard.”
On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis medicine bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.
With corona virus (COVID-19) spreading globally, IDA Foundation is closely monitoring the developments to ensure we are able to respond to any changes. This past week, we were glad to support the Asian Infrastructure Investment Bank (AIIB) by supplying medical goods to be used in the corona virus response in China.
As procurement agent for Stop TB /GDF, we are glad to share this news update as announced by the Stop TB partnership during the 50th Union Conference for Lung Health in Hyderabad, India.
IDA Foundation attended the Portage Inaugural Meeting in Centro Sharjah, UAE. The meeting aims to discuss ways to simplify treatment and access for Children with Cancer in low and middle income countries.